Page last updated: 2024-10-26

dipyridamole and Fallot's Tetralogy

dipyridamole has been researched along with Fallot's Tetralogy in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukushima, R1
Yoshiyuki, R1
Machida, N1
Matsumoto, H1
Kim, S1
Hamabe, L1
Huai-Che, H1
Fukayama, T1
Suzuki, S1
Aytemiz, D1
Tanaka, R1
Yamane, Y1

Other Studies

1 other study available for dipyridamole and Fallot's Tetralogy

ArticleYear
Extreme tetralogy of Fallot in a dog.
    The Journal of veterinary medical science, 2013, Volume: 75, Issue:8

    Topics: Angiocardiography; Animals; Captopril; Digoxin; Dipyridamole; Dog Diseases; Dogs; Echocardiography;

2013